Search results for " Adverse Events"

showing 10 items of 52 documents

French Endocrine Society Guidance on endocrine side effects of immunotherapy.

2018

The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing…

PD-L1Cancer Researchmedicine.medical_specialtyHypophysitisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmune checkpoint inhibitorsimmune checkpoint inhibitorEndocrine System DiseasesGuidelines and GuidanceEndocrinologyAntineoplastic Agents ImmunologicalPD-1medicineAdrenal insufficiencyEndocrine systemHumansIn patientthyrotoxicosisIntensive care medicinediabetesbusiness.industryCommon Terminology Criteria for Adverse EventsImmunotherapymedicine.diseaseFrequent usehypophysitisOncologyCTLA-4FranceImmunotherapyhypothyroidismbusinessadrenal insufficiencyEndocrine-related cancer
researchProduct

Risk assessment in ginecology and obstetrics in Sicily: an approach based on Wolff's Criteria

2013

Objectives To apply Wolff’s Criteria to hospital discharge records (HDR) in order to detect adverse events worthy of further study. Methods Gynecology and Obstetrics Units of three Sicilian hospitals were considered and HDR regarding ordinary and day hospital admissions in 2008 were collected. A matched case-control study was designed, by random selection of 10 controls at maximum for each case. Matching was performed on the variables age and speciality of admission (gynecology or obstetrics). Results Out of a total of 7011 HDR examined, 114 cases were identified with Wolff’s Criteria. Multivariate analysis confirmed a statistically significant association with the origin of admission, diag…

Patient TransferReoperationGenital Neoplasms FemaleSettore MED/42 - Igiene Generale E ApplicataPatient ReadmissionRisk AssessmentSettore MED/01 - Statistica MedicaGynecologic Surgical ProceduresPregnancyRisk FactorsAmbulatory CarePrevalenceHumansHospital MortalityObstetrics and Gynecology Department HospitalRisk ManagementLength of StayDelivery ObstetricQuality ImprovementPatient DischargeIntensive Care UnitsItalyCase-Control StudiesWolff’s Criteria Adverse Events Clinical Risk Obstetrics GynecologyFemalePatient SafetyEmergencies
researchProduct

Impact of universal vaccination against varicella in Italy: Experiences from eight Italian Regions.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13-15 months and 5-6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

Pediatricsmedicine.medical_specialtyImmunologyadverse events following varicella immunizationVaricellaSettore MED/42 - Igiene Generale E ApplicataEnvironmental healthmedicineImmunology and AllergyHealth policyChickenpox VaccinePharmacologyChickenpoxbusiness.industryIncidence (epidemiology)immunization coverageHealth services researchUniversal Varicella VaccinationnotificationsVaricella; Universal Varicella Vaccination; Notifications; Hospitalizations; Immunization coverage; Adverse effectsmedicine.diseaseVaccinationImmunizationVaccination coverageUniversal Varicella Vaccination; Varicella; adverse events following varicella immunization; hospitalizations; immunization coverage; notificationsbusinesshospitalization
researchProduct

Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment

2020

Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.

Settore MED/38 - Pediatria Generale E SpecialisticaDMARDs juvenile idiopathic arthritis Dermatologic adverse events
researchProduct

Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

2021

This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years of follow-up, in both antiretroviral treatment (ART)-naive and experienced people living with HIV (PLWH). This is a prospective multi-center cohort study enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using the Kaplan-Meier survival curve. The Cox proportional-hazards model was used for estimating the hazard ratio (HR) of DTG discontinuation for any cause, and for adverse events (AEs). Nine hundred sixty-three PLWH were included, 25.3% were women and 28.0% were ART-naive. Discontinuations for any causes were 10.1 [95% confidence interval (95% CI) 8.9-1…

adverse events; dolutegravir; durability; HIV; safety; toxicity; virolgical failure; Cohort Studies; Female; Heterocyclic Compounds 3-Ring; Humans; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Anti-HIV Agents; HIV InfectionssafetyPediatricsmedicine.medical_specialtySettore MED/17 - Malattie InfettivePyridonesAnti-HIV AgentsOxazineHuman immunodeficiency virus (HIV)adverse eventHIV Infectionsvirolgical failurePyridonemedicine.disease_cause3-RingHIV Infections.PiperazinesCohort Studieschemistry.chemical_compoundHeterocyclic CompoundsHIV; adverse events; dolutegravir; durability; safety; toxicity; virolgical failureOxazinesAntiretroviral treatmentMedicineHumansProspective StudiesAdverse effectPiperazinebusiness.industryPublic Health Environmental and Occupational HealthHIVtoxicityAnti-HIV AgentMiddle Agedadverse eventsDiscontinuationdolutegravirvirolgical failure.Prospective StudieInfectious DiseaseschemistryDolutegravirdurabilityObservational studyFemaleCohort StudiebusinessHeterocyclic Compounds 3-RingHuman
researchProduct

Life events and primary monosymptomatic nocturnal enuresis: A pediatric pilot study

2017

Introduction: The association between primary monosymptomatic nocturnal enuresis (PMNE) and behavioral disorders was highlighted frequently, suggesting psychiatric origin. On the other hand, there is no difference between the incidence of mental disorders in children with PMNE and controls, although the psychological genesis could provide additional secondary forms, in which the child might react to stressful events with the resumption of involuntary urination at night, with a possible alteration of bowel control due to a high vulnerability to stressors. The purpose of this study is assessing the stressful events of life in a sample of children with PMNE. Materials and methods: 56 subjects …

life adverse eventPrimary monosymptomatic nocturnal enuresiSettore M-PSI/04 - Psicologia Dello Sviluppo E Psicologia Dell'EducazioneMedicine (all)Coddington life events scalePMNECoddington life events scales; life adverse events; PMNE; Primary monosymptomatic nocturnal enuresis; Medicine (all)Settore MED/39 - Neuropsichiatria Infantile
researchProduct

Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofraction…

2020

Objectives: To investigatewhether assessmentwith two geriatric screening tools shows a correlationwith clinical outcomes of patients aged 65 years or more, with early-stage Non-Small Cell Lung Cancer (es-NSCLC) treated with hypofractionated stereotactic radiotherapy. Methods: FromMarch 2014 to June 2018we retrospectively evaluated 42 patientswith stage I and II lung tumors. Patients were assessed with Charlson Comorbidity Index (CCI) and G8 screening tool. Median age was 74 years (range, 65–91). Stereotactic radiotherapy was performed with Helical Tomotherapy delivering 50–70 Gray (Gy) in 8–10 fractions. Toxicity was evaluated using Common Terminology Criteria for Adverse Events v4.0 criter…

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentRadiosurgeryChest painTomotherapySettore MED/01 - Statistica Medica03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungmedicineHumansProspective Studies030212 general & internal medicineStage (cooking)Adverse effectProspective cohort studyLung cancerEarly Detection of CancerAgedRetrospective StudiesLung cancer Radiation therapy G8 Charlson comorbidity indexbusiness.industryCommon Terminology Criteria for Adverse EventsPrognosismedicine.diseaseTreatment OutcomeOncology030220 oncology & carcinogenesisCohortDose Fractionation RadiationRadiologyGeriatrics and Gerontologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessJournal of Geriatric Oncology
researchProduct

PReS-FINAL-2088: Risk of severe adverse events in juvenile idiopathic arthritis and pediatric-onset inflammatory bowel disease, treated with anti-tnf…

2013

Introduction: Severe adverse events have been described in children affected by Juvenile Idiopathic Arthritis (JIA) and Inflammatory Bowel Disease (IBD) treated with anti-tnf drugs. Objectives: To define the risk of severe adverse events in patients with JIA and IBD treated with anti-tnf drugs. Methods: This is a retrospective cohort study. All patients with JIA and IBD attending the "IRCCS Burlo Garofolo" of Trieste from 2000 to 2012 were enrolled. They were divided into 2 groups on the basis of the presence or absence of anti-tnf exposure. Severe adverse events were considered the followings: a) infections needing anti-tnf permanent suspension and/or hospitalization; b) autoimmune disease…

medicine.medical_specialtyPathologyPediatric onsetArthritismacromolecular substancesInflammatory bowel diseaseanti-TNF pediatric rheumatology arthritis adverse events inflammatory bowel diseaseRheumatologyinflammatory bowel diseaseInternal medicinemedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child HealthPediatric rheumatologyAdverse effectbusiness.industryanti-TNFmedicine.diseaseadverse eventsdigestive system diseasesRheumatologypediatric rheumatologyarthritisPediatrics Perinatology and Child HealthPoster PresentationTumor necrosis factor alphabusiness
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct